Статин – ассоциированные мышечные поражения: возможные риски и потенциал фармакогенетического подхода к их предупреждению

А. А.  Nekrasov; L. A. Lugovaya; T. A. Nekrasova; Е. S. Timoshchenko

doi:10.34687/2219-8202.JAD.2023.03.0003

Authors

А. А. Nekrasov FSBEI HE PRMU MOH Russia
L. A. Lugovaya FSBEI HE PRMU MOH Russia
T. A. Nekrasova ФГБОУ ВО «ПИМУ» Минздрава России, Нижний Новгород
Е. S. Timoshchenko City Cardiology Dispensary of City Clinical Hospital № 5, Nizhny Novgorod

DOI:

https://doi.org/10.34687/2219-8202.JAD.2023.03.0003

Abstract

Statins are related to the most effective lipid-lowering drugs but the use of them can be associated with side effects including statin-associated muscle symptoms (SAMS). New experimental data have revealed additional and probably underestimated consequences of SAMS including the possibility of damage not only to skeletal muscles but also to the myocardium. Accordingly the patients receiving statins and having SAMS with subclinical damage of the heart muscle can be identified in clinical practice. These patients need a close attention of cardiologists for the assessment of their prognosis and therapy modification. Genotyping can have a high potential to identify a group of patients with a high probability of cardiac myopathic disorders. The risk of SAMS with subclinical myocardial injury confirmed by pharmacogenetic methods can be a promising criterion for personalized approaches to the treatment of patients with atherosclerotic cardiovascular diseases.

This review presents 1) the assessment of the epidemiological scale, clinical and biochemical markers of SAMP, 2) literature sources confirming the possibility of cardiac damage in conditions of SAMS, 3) analysis of the potential of pharmacogenetics to identify individuals with a predisposition to muscle disorders.

Downloads

Download data is not yet available.

Author Biographies

А. А. Nekrasov, FSBEI HE PRMU MOH Russia

Head of the Department of Faculty and Polyclinic Therapy of FSBEI HE PRMU MOH Russia

L. A. Lugovaya, FSBEI HE PRMU MOH Russia

Assistant of the Department of Endocrinology and Internal Diseases, Federal State Budgetary Educational Institution of Higher Education "PIMU" of the Ministry of Health of Russia

Е. S. Timoshchenko, City Cardiology Dispensary of City Clinical Hospital № 5, Nizhny Novgorod

Head of the City Cardiological Dispensary of City Clinical Hospital No. 5, Nizhny Novgorod

References

Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy. Circulation: Genomic and Precision Medicine. 2018;11:e002320.

Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Bubnova MG, Balakhonova TV, Gurevich VS, Kachkovsky MA, Konovalov GA, Konstantinov VO, Malyshev PP, Pokrovsky SN, Sokolov AA,Sumarokov AB, Gornyakova NB, Obrezan AG, Shaposhnik II. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. JAD. 2020;1(38):7-42 (КухарчукВ.В., ЕжовМ.В., СергиенкоИ.В., АрабидзеГ.Г., БубноваМ.Г., БалахоноваТ.В.,ГуревичВ.С., КачковскийМ.А., КоноваловГ.А., КонстантиновВ.О., МалышевП.П., ПокровскийС.Н., СоколовА.А., СумароковА.Б., ГорняковаН.Б., ОбрезанА.Г., ШапошникИ.И. Диагностикаикоррекциянарушенийлипидногообменасцельюпрофилактикиилеченияатеросклероза. АиД. 2020;1(38):7-42).

Muntean DM, Thompson PD, Catapano AL, StasiolekM, FabisJ, Muntner P, Serban M-C, Banach M. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017;22(1):85–96.

Toth PP, PattiAM,Giglio RV, Nikolic D,Castellino G,Rizzo M, Banach M.. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs. 2018; 18(3): 157–173.

Chu C-S, Tseng P-T,Stubbs B,Chen T-Y,Tang C-H,Li D-J, Yang W-C, Chen Y-W, Wu C-K, Veronese N, Carvalho AF, Fernandes BS, Herrmann N, Lin P-Y. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep. 2018; 8: 5804.

Ramakumari N,Indumathi B,Katkam SK,Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018 Dec;70(3):120–125.

Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am CollCardiol. 2017;69:1386–1395.

SaowalakTurongkaravee, JiraphunJittikoon, ThitiyaLukkunaprasit, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A.A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021 Jun;21(3):296-307.

Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K,Aronow WS,Athyros V,Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Dimitri P Mikhailidis DP. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1-23.

Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J ClinLipidol. 2012;6:208–215.

Godoy JC,Niesman IR,Busija AR, Kassan A,Schilling JM,Schwarz A, Alvarez EA,Dalton ND,Drummond JC,Roth DM,Kararigas G,Patel HH, AE. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2019 Jan; 33(1): 1209–1225.

Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JDF, Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–585.

Peyser B, Perry E, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Y-L Trujilio G, Voora D. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. CircGenomPrecis Med. 2018;11(9) :e002228.

Jiang J,TangQ,FengJ,DaiR,Wang Y, Dai R, Wang Y, Yang Y, Tang X, Deng C, Zeng H, Zhao Y, Zhang F. Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. Springerplus. 2016; 5(1): 1368.

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J ClinLipidol. 2014;8:S58–S71.

Ochs-Balcom HM, Nguyen LM, Ma C, Isackson PJ, Luzum JA, Kitzmiller JP, Tarnopolsky M, Weisman M, Christopher-Stine L, Peltier W, Wortmann RL, Vladutiu GD. Clinical Features Related to Statin-Associated Muscle Symptoms. Muscle Nerve. 2019; 59(5): 537–543.

Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T, Mamcarz A, Broncel M, Tomasik T, Rysz J, Jankowska-Zduńczyk A, Hoffman P, Mastalerz-Migas A. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci. 2017;13:1–45.

Stroes E S, Thompson P D, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, Backer GD, Krauss RM, Laufs U, Santos PD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–1022.

Burch PM, Greg Hall D, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NMP, Lane P, John-Michael Sauer Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE. Evaluation of the relative performance of drug-induced skeletal muscle injury biomarkers in rats. Toxicol Sci. 2016;150:247–256.

Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, MeersGM, Ruebel M, Laughlin MH, DellspergerKC, Fadel PJ, Thyfault JP. Simvastatin impairs exercise training adaptations.J. Am. Coll. Cardiol.2013;62:709–714

Allard NAE, Schirris TJJ, Verheggen RJ, Russel FGM, Rodenburg RJ,Smeitink JAM, Thompson PD, Hopman MTE, Timmers S. Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism. J. Clin. Endocrinol. Metab.2018;103:75–84

Ghavami S, Yeganeh B, Stelmack GL, Kashani HH, Sharma P, Cunnington R, Rattan S, Bathe K, Klonisch T, Dixon IM, Freed DH, Halayko AJ. Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts.Cell Death Dis. 2012;3:e330.

Priti K, Agrawal A, Ranwa BL. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. Indian Heart J. 2017; 69(4): 453–457.

Trentini A,Spadaro S,Rosta V,Manfrinato MS,Cervellati C,Corte FD,Hanau S, Volta CA, Bellini T. Fast skeletal troponin I, but not the slow isoform, is increased in patients under statin therapy: a pilot study. Biochem Med (Zagreb). 2019;29(1):010703.

Mamoshina P,Rodriguez B,Bueno-Orovio A. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med. 2021;2(3):100216.

Krasi G,Precone V,Paolacci S,Stuppia L,Nodari S,Romeo F,Perrone M,Bushati V,Dautaj A,Bertelli M. Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases. Acta Biomed. 2019;90(10): 7–19.

Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodríguez-Antona C. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med. 2018;20(6):622-629.

Maxwell WD, Ramsey LB, Johnson SG. Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia. Pharmacotherapy. 2017;37(9):1172–1190.

Sissung TM, Goey AKL, Ley AM, Strope JD, Figg WD. Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. Methods Mol Biol. 2014;1175:91-120

García B, Sanguesa E, Concha J, Lomba L, López V, Gutiérrez JN, Estepa A. Strengthening pharmacogenetics. Abstracts from the 51st European Society of Human Genetics Conference: Posters. Eur J Hum Genet. 2019;27(1):1–688.

Arrigoni E, Re MD, Fidilio L, Fogli S, Danesi R, Paolo AD. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. Int J Mol Sci. 2017;18(1):104.

Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705.

The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. The N Engl J Med. 2008;359(8):789-799.

Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. PharmacogenomicsandPersonalizedMedicine 2016:9: 97–106.

Lugovaya LA, Nekrasova TA, Strongin LG, Beliaeva NG. Compensated hypothyroidism and statin administration: symptoms of muscle damage and muscle metabolism disorders. ProblemsofEndocrinology. 2019;65(6):408-416. Russian. (Луговая Л.А., Некрасова Т.А., Стронгин Л.Г., Беляева Н.Г. Компенсированный гипотиреоз и прием статинов: симптомы поражения мышц и нарушения мышечного метаболизма.Проблемы эндокринологии. 2019;65:6:408-416).

Lugovaya LA. Clinical and laboratory signs of muscle damage in patients with compensated hypothyroidism during treatment with statins .: dis. ... Cand. medical sciences: 01/14/02: protected 02/20/19: approved 07/01/19. Nizhny Novgorod. 2018:156 p. Russian. (Луговая Л.А. Клинико-лабораторные признаки поражения мышц у больных компенсированным гипотиреозом нафонелечениястатинами.: дис. … канд. мед.наук: 14.01.02: защищена 20.02.19: утв. 01.07.19.НижнийНовгород. 2018; 156 с.)

KhokhlovAL, PozdnyakovNO, RybachkovaJV, EmelianovES, KhokhlovAA, MiroshnikovAE, PozdnyakovSO. Pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis. The Russian Archives of Internal Medicine. 2018; 8(1): 45-52. Russian (ХохловА.Л., ЯворскийА.Н., ПоздняковН.О., РыбачковаЮ.В., ЕмельяновЕ.С., ХохловА.А., МирошниковА.Е., ПоздняковС.О. Клинико-генетическиеаспектытерапиипациентовсатеросклерозом. Архивъ внутренней медицины. 2018; 8(1): 45-52).

SirotkinaА, Khokhlov A, Voronina E. Prevalence of Gene Polymorphism SLCO1B1 in Patients with Dyslipidemia and Systemic Atherosclerosis in Russian Population. Clinical Therapeutics. 2013;35(8):67.

Zubiaur P, Benedicto MD,Villapalos-García G, Navares-Gómez M, Mejía-Abril G, Manuel Román M, Martín-Vílchez S, Ochoa D, Abad-Santos F. SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. J Pers Med. 2021;11(3):204.

Vassy JL,Gaziano JM, Green RC, Ferguson RE, Advani S, Miller SJ, Chun S, Hage AK, Seo S-J, Majahalme N, MacMullen L, Zimolzak AJ, Brunette CA. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol. A Randomized Clinical Trial. JAMA Netw Open. 2020;3(12):e2027092.

Dagli-Hernandez C, Freitas RCC, Marçal ESR, Gonçalves RM, Faludi AA, Borges JB, Bastos GM, Los B, Mori AA,Bortolin RH, Ferreira GM, Oliveira VF, HirataTDC, Hirata MH, Hirata RDC. Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report. Ann Transl Med. 2021;9(1):76.

Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, Marino F, Cosentino M. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J ClinPharmacol. 2014;70(5):539–547.

Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J ClinLipidol. 2011;5(2):91–96.

DeGorter MK, Tirona RG, Schwarz UI, Choi Y-H, Dresser GR, Suskin N, Myers K, Zou GY, Iwuchukwu O, Wei W-Q, Wilke RA, Hegele RA, Kim RB. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. CircCardiovasc Genet. 2013;6(4):400–408.

United States Federal Drug Administration. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. US FDA Safety Announcement 06-08-2011. Washington, DC: FDA; 2011

Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics and Personalized Medicine. 2016:9 97–106.

Licito A, Marotta G, Battaglia M, Benincasa G, Mentone L, Grillo MR, De Lucia V, Leonardi G,Bignucolo A, Comello F, Francia RD, Lucia DD. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results. Eur Rev Med Pharmacol Sci. 2020;24(1):469-477.

Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case–control study.Atherosclerosis. 2010;211(1):28–29.

Luzum JA, Kitzmiller JP, Isackson PJ, Ma C, Medina MW, Dauki AM, Mikulik EB, Ochs-Balcom HM, Vladutiu GD. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab. 2015;21(4):622–627.